Detobio Consulting
Early development strategy, due diligence for rare disease, hematology and cardiovascular.
A one-person practice: every engagement is led personally, end to end, by a PhD scientist with 15+ years in biopharma strategy and business development.
Tell me about your assetOne for companies building their plan, one for companies sitting on data. Both backed by partnering support.
Term sheets, IP alignment and governance, then the day-to-day management that keeps an alliance from stalling after signing. 10+ licensing agreements negotiated across oncology, rare disease and neuroscience.
Engagement: advisory retainer, embedded project or fixed-fee deliverable.
Two recent engagements, anonymised.
An academic spin-off developing a new antibody against a new target in non-oncology hematology had strong preclinical data but no roadmap to the clinic.
Built the business plan and the product development plan: scientific review, regulatory and manufacturing strategy, clinical roadmap, competitive landscape, budget and timeline, integrated into the investor pitch.
The plan supported initial funding discussions with VCs and drew positive investor feedback.
A completed study and its clinical study report sat idle: priorities had moved on and the results were never published.
Mined the study data for new insights, prepared the manuscript and defined the publication and scientific communication strategy.
The company's scientific model was revised, and a scientific communication strategy was defined and implemented.
I hold a PhD in biology (Institut Pasteur) and have spent 15+ years in biopharma strategy, business development and pipeline planning, at Roche, Conectus and Acticor Biotech. I have triaged 27+ concepts in oncology and rare disease, led commercial due diligence with large pharma and negotiated 10+ licensing agreements.
Detobio Consulting, founded in 2025, brings that experience to biotechs without an in-house strategy team. My approach is direct and data-driven: recommendations rest on your results and your competitive landscape, not on a generic playbook.
Elie Toledano, PhD
Founder & Principal Consultant
Detobio Consulting